ProPhase Labs, Inc. Annual report pursuant to Section 13 and 15(d)

EARNINGS PER SHARE (Details Textual)

EARNINGS PER SHARE (Details Textual)	12 Months Ended
EARNINGS PER SHARE (Details Textual)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common stock equivalents were in-in-the-money
Earnings Loss Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	598,609		177,035
Common stock equivalents out-of-the-money
Earnings Loss Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	26,500	472,500	114,000

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References + Details